Document is current
Any future updates will be listed below
-
Authors
Ebbers, Hans C. https://orcid.org/0000-0002-9553-9863
Taylor, Peter C. https://orcid.org/0000-0001-7766-6167
Leng, Xiaomei https://orcid.org/0000-0002-0215-9176
Wei, Wei https://orcid.org/0000-0003-1691-9305
Kinsella, Niamh M. https://orcid.org/0009-0004-9071-4935
Zhou, Yinbo
Yang, Xiaolei https://orcid.org/0009-0007-5099-9464
Chamberlain, Paul https://orcid.org/0000-0002-8273-140X
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03606876 at ClinicalTrials.govnct03830203 at ClinicalTrials.govDocuments that mention this clinical trial
A Comparison of the Immunogenicity of Intravenous BAT1806, a Tocilizumab Biosimilar, and Its Reference Product
https://doi.org/10.1007/s40744-025-00760-y
Documents that mention this clinical trial
A Comparison of the Immunogenicity of Intravenous BAT1806, a Tocilizumab Biosimilar, and Its Reference Product
https://doi.org/10.1007/s40744-025-00760-y
-
Funding
Funding for this research was provided by:
Biogen GmbH
- License Information
-
More Information
Article History
Received: 20 December 2024
Accepted: 18 March 2025
First Online: 8 April 2025
Declarations
:
: Hans C. Ebbers, Wei Wei and Niamh M. Kinsella are Biogen employees and may hold stock, stock options or both in Biogen. Xiaomei Leng has nothing to disclose. Peter C. Taylor has received grant/research support from Galapagos (made to institution); consulting fees and/or honoraria from AbbVie, Biogen, Eli Lilly and Company, Fresenius Galapagos, Gilead Sciences, GlaxoSmithKline, Janssen, Nordic Pharma, Pfizer Inc, Sanofi, Immunovant and UCB. Yinbo Zhou and Xiaolei Yang are Bio-Thera Solutions Ltd employees and may hold stock, stock options or both in Bio-Thera Solutions Ltd. Paul Chamberlain has received consulting fees from Biogen.
: BAT1806-002-CR was conducted in accordance with the Declaration of Helsinki and/or all relevant local regulations, in compliance with the International Council for Harmonisation Good Clinical Practice guidelines and according to the appropriate regulatory requirements in the countries where the study was conducted. BAT1806-001-CR was approved by The First Bethune Hospital of Jilin University, Changchun, Jilin, China. The patients/participants provided their written informed consent to participate in this study. Patient consent was not applicable for this comparison article.
